Month: September 2026

LANGHORNE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced the date for the investor update call referenced in its August 17, 2026 earnings release, at which time the Company indicated it expected to host the call on or around September 15, 2026. The Company will now host the call on September 24, 2026, at 4:15 p.m. Eastern Time.

The call will provide investors with an update on the Company’s operational progress, commercialization initiatives, and other corporate matters. Details for accessing the call will be announced separately.

About NEXGEL, INC.
NEXGEL, through its Bionx Surgical division, is a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience. Bionx has a strong offering of products including Biovance (human amniotic membrane allograft), Biovance 3L (tri-layer human amniotic membrane allograft), Interfyl (human connective tissue matrix), SilverSeal (antimicrobial hydrogel wound dressing), and an expansive opthalmic portfolio of placental derived ocular allografts (LUCENT, single layer, RADIANT, dual layer, and VIVID, triple layer). Additionally, NEXGEL is a provider of healthcare, beauty, and over the counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. In addition to the above, NEXGEL brands include Hexagels^®, Turfguard^®, Kenkoderm^® and Silly George^®. NEXGEL also has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, statements regarding the timing, content, and conduct of the anticipated investor update call. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com

MINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) — PetVivo Animal Health, Inc. (“PetVivo”), in cooperation with its parent, PetVivo Holdings, Inc. (OTCQX: PETV), and its other subsidiaries, Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for equine and companion animals today announced its veterinary conference and exhibition schedule for the remainder of 2026 and through April 2027.

The conference schedule is designed to provide PetVivo with continued opportunities to engage directly with veterinarians, specialists, practice owners and other animal health professionals; increase awareness of Spryng® with OsteoCushion® Technology; provide clinical and product education; and strengthen relationships with veterinary practices across the companion animal and equine markets.

The schedule includes several of the veterinary profession’s leading educational and industry events. PetVivo will begin this week at the Southwest Veterinary Symposium (“SWVS”) in San Antonio, where the Company will exhibit and sponsor a canine joint-injection wet lab. SWVS features more than 400 hours of RACE-approved continuing education and more than 250 exhibitors, providing PetVivo an opportunity to engage veterinarians through both clinical education and direct interaction.

PetVivo also plans to participate in an event hosted by Veterinary Growth Partners (“VGP”), whose network includes more than 7,000 independent veterinary hospitals. The VGP relationship provides PetVivo with an opportunity to engage with independent veterinary practices and practice leaders who represent an important segment of the companion animal health market.

The schedule further includes the American College of Veterinary Surgeons (“ACVS”) Surgery Summit, which brings together veterinary surgeons and other professionals focused on advanced patient care; and the American Association of Equine Practitioners (“AAEP”) Annual Convention, the world’s largest meeting of equine veterinarians. AAEP’s community includes more than 9,000 veterinarians and veterinary students, making the convention an important opportunity for PetVivo to expand awareness of Spryng within the equine veterinary community.

In early 2027, PetVivo plans to participate in VMX 2027 in Orlando and WVC Vegas 2027, two of the veterinary profession’s major educational and industry gatherings. PetVivo will also participate in the International Veterinary Academy of Pain Management (“IVAPM”) Pain Management Forum in Minneapolis, an event specifically focused on advancing the prevention, detection and management of pain in animals.

“We are entering a very active period of direct engagement with the veterinary community, beginning this week at SWVS and continuing through some of the profession’s most important meetings,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Our goal is to put Spryng and the clinical information supporting its use directly in front of veterinarians and other veterinary professionals who manage joint-related conditions and lameness every day. Whether we are meeting independent veterinary practices through VGP, veterinary surgeons at ACVS, equine practitioners at AAEP or the broader veterinary community at VMX and WVC, these events provide valuable opportunities to educate clinicians, listen to their needs, strengthen relationships with existing customers and introduce Spryng to new veterinary practices. We believe consistent clinical education and direct veterinarian engagement are important components of our strategy to expand awareness and adoption of Spryng.”

Spryng^® with OsteoCushion^® Technology is PetVivo’s lead commercial product and is a veterinarian-administered, intra-articular veterinary medical device for the management of lameness and other joint-related afflictions, including osteoarthritis, in companion animals and horses.

PetVivo’s currently scheduled 2026–2027 conferences and exhibitions include:

Event Name	Start Date	End Date	Location
SWVS 2026	September 17, 2026	September 20, 2026	San Antonio, TX
ACVS 2026	October 8, 2026	October 10, 2026	Charlotte, NC
Auburn Annual Conference 2026	October 29, 2026	October 31, 2026	Auburn, AL
VGP Membership Event	November 7, 2026	November 8, 2026	Charleston, SC
AAEP 2026	December 6, 2026	December 10, 2026	Las Vegas, NV
VMX 2027	January 16, 2027	January 20, 2027	Orlando, FL
Midwest Vet Conference 2027	February 18, 2027	February 20, 2027	Columbus, OH
WVC Vegas 2027	February 28, 2027	March 3, 2027	Las Vegas, NV
IVAPM 2027	April 3, 2027	April 5, 2027	Minneapolis, MN

The conference schedule reflects PetVivo’s continued commitment to veterinary education and to increasing direct engagement with the veterinarians and practice leaders responsible for advancing animal health and patient care.

For more information about PetVivo Holdings, Inc. and its innovative products please contact info1@petvivo.com or visit https://petvivo.com/, https://www.petvivoanimalhealth.com/ and https://www.sprynghealth.com.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product, SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking Statements

The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Autonomous vehicle test fleets generate more video than they can store or move. Beamr’s lossless compression keeps footage bit-exact at capture in the test vehicles, while reducing file sizes by 47%.

Join the demonstration at AutoSens Europe, Barcelona, September 22–24, stand 131

Herzliya, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (Nasdaq: BMR), a leader in video optimization technology and solutions, today launched lossless compression as part of ML-Safe video data compression for autonomous vehicles (AV). The ML-Safe solution, enabling AV teams to reduce video data file sizes while preserving ML model accuracy, now covers lossy compression that is confirmed against the model’s own accuracy metrics, and lossless compression that is bit-exact by definition.

Beamr will demonstrate its ML-Safe solution at AutoSens Europe in Barcelona, September 22–24, stand 131.

AV test fleets generate more video than they can store or move. A single test vehicle runs as many as 16 cameras, and 11 is typical. They can record tens of terabytes in one shift. Cameras commonly produce 12-bit Bayer, the camera sensor’s raw output before it enters the AV pipeline. Until now AV teams often had to keep the footage raw, without compression, since the encoder in the test vehicle did not accept the 12-bit Bayer format. As a result, AV teams had two choices: keep the raw footage and pay for it in drives, swaps and upload time, or delete video data and hope a future model never needs it.

Beamr’s lossless compression addresses the AV teams need by taking the 12-bit Bayer and compressing it with zero loss. In addition, data-capture capacity is almost doubled, data is preserved, and no new hardware is needed. The work runs on the video encoder that is integrated in the GPU already in the data logger. Since the encoder runs separately from the GPU compute cores, compression draws on capacity the AI models are not using.

Beamr’s lossless compression is designed to compress multiple cameras in real time on the video encoder of a single GPU. In Beamr’s testing on 12-bit Bayer recordings from 8-megapixel cameras, compressed files were 47% smaller than raw.

“Through our joint work with AV and ADAS companies we identified their need for lossless compression at the edge, in the data-collection vehicle, supporting multiple camera streams in real time. So we built it,” said Sharon Carmel, Beamr CEO. “By running Beamr’s lossless solution accelerated by GPUs, we are demonstrating a solution that reduces the data at the point of capture while preserving every bit of the original camera data.”

“Lossless compression was the piece missing from Beamr’s ML-Safe video data compression solution for AV,” said Dani Megrelishvili, Beamr CPO. “We are already offering ML-Safe lossy compression tested against the team’s own models. Now teams that need every bit kept can also compress in the test vehicle. This puts Beamr at the point where data is created, and what is saved there is saved again at every step that follows: on the drives, on the way to the cloud, and in every training run that reads it.”

Autonomous vehicle and ADAS teams can test Beamr ML-Safe compression on their own video data and pipeline design. To book a meeting at AutoSens Europe, Barcelona (stand 131), or request lossless evaluation on your data, visit beamr.com/lossless.

About Beamr

Beamr (Nasdaq: BMR) is a world leader in content-adaptive video compression, trusted by top media companies including Netflix and Paramount. Beamr’s perceptual optimization technology (CABR) is backed by 53 patents and a winner of Emmy® Award for Technology and Engineering. The innovative technology reduces video file sizes by up to 50% while preserving quality and enabling AI-powered enhancements.

Beamr powers efficient video workflows across high-growth markets, such as media and entertainment, user-generated content, machine learning, and autonomous vehicles. Its flexible deployment options include on-premises, private or public cloud, with convenient availability for Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI) customers.

For more details, please visit www.beamr.com or the investors’ website www.investors.beamr.com and follow us on Linkedin and X.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this communication may include, among other things, statements about Beamr’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations and financial performance and condition, including statements relating to the capabilities, performance, applications, market opportunities, adoption, commercialization and potential benefits of the Company’s technology, products and solutions, and the Company’s ability to execute its growth strategy and create commercial opportunities. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on February 26, 2026 and in subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
investorrelations@beamr.com

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar.

“We are pleased to see Impact reach this important milestone in its proposed Business Combination with Zoar,” said Jason Grady, Chief Executive Officer of DSS, Inc. “The filing of the Form F-4 demonstrates continued momentum toward the proposed transaction and represents another step in the evolution of Impact. We believe the combination has the potential to strengthen Impact’s platform, expand its opportunities for future growth, and ultimately create meaningful value for DSS and our shareholders.”

The Registration Statement includes a preliminary proxy statement of Impact and a prospectus of Zoar relating to the proposed transaction. The filing remains subject to SEC review and has not yet been declared effective.

The proposed Business Combination remains subject to a number of conditions, including the Registration Statement being declared effective by the SEC, approval of the transaction by Impact stockholders, approval of the listing of Zoar ordinary shares on NYSE American, and the satisfaction or waiver of other conditions contained in the applicable merger and share exchange agreement.

The filing of the Registration Statement does not mean that the Registration Statement has been declared effective, that the SEC has completed its review, that Impact stockholders have approved the proposed transaction, or that the transaction will be completed.

About DSS, Inc.

DSS, Inc. (NYSE American: DSS) is a multinational company operating across multiple business lines including product packaging, biotechnology, commercial lending, and securities and investment management. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit www.dssworld.com.

Additional Information and Where to Find It

In connection with the proposed Business Combination, Zoar Limited has filed with the SEC a Registration Statement, which includes a preliminary proxy statement of Impact that also constitutes a prospectus of Zoar. Investors and security holders are urged to read the Registration Statement, the proxy statement/prospectus and any other relevant documents filed or to be filed with the SEC, as well as any amendments or supplements to those documents, carefully and in their entirety when they become available because they contain or will contain important information regarding the proposed transaction.

Copies of these documents may be obtained without charge through the SEC’s website.

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor does it constitute a solicitation of any vote, proxy, consent or approval in connection with the proposed transaction. No offer or sale of securities shall be made except in accordance with applicable securities laws.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, among others, statements concerning the proposed Business Combination, the anticipated completion of the transaction, the effectiveness of the Registration Statement, stockholder and regulatory approvals, the proposed listing of Zoar ordinary shares and the anticipated ownership of PubCo following the transaction. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. DSS undertakes no obligation to update any forward-looking statements except as required by law.

Investor Relations

DSS, Inc.
ir@dssworld.com
+1 (585) 565-2422

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) — Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) (“Zoar Labs”), which includes Impact’s preliminary proxy statement. The F-4 Registration Statement is available through the SEC’s website at www.sec.gov under the name “Zoar Limited”.

The management of Impact believes the filing of the Registration Statement is a major milestone in the path to closing. The completion of the Business Combination and the listing of the ordinary shares of PubCo shall be subject to, among others, the Registration Statement being declared effective by the SEC, approval of the transaction by Impact stockholders, approval of the listing of PubCo shares on NYSE American, and satisfaction or waiver of the other conditions in the merger and share exchange agreement.

The merger of Impact Biomedical Inc. and Zoar, upon approval and closing, is expected to result in a pharmaceutical company focused on the development and supply of Active Pharmaceutical Ingredients and intermediates for special therapeutic treatment areas.

Additional Information and Where to Find It
In connection with the proposed transaction, Zoar Limited has filed with the SEC a Registration Statement that includes a preliminary proxy statement/prospectus (a “Proxy Statement/Prospectus”). After the Registration Statement is declared effective, a definitive Proxy Statement/Prospectus will be mailed to Impact’s stockholders as of a record date to be established by Impact’s board of directors for voting on the Business Combination. Impact may also file other relevant documents regarding the Business Combination with the SEC. Impact’s stockholders and other interested persons are advised to read, once available, the preliminary Proxy Statement/Prospectus and any amendments thereto and, once available, the definitive Proxy Statement/Prospectus, in connection with Impact’s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Business Combination, because these documents will contain important information about Impact, Zoar Labs, PubCo and the Business Combination. Stockholders of Impact may also obtain a copy of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: Impact’s Chief Executive Officer at 275 Wiregrass Pkwy, West Henrietta, NY 14586.

Participants in the Solicitation
Impact, PubCo, Zoar Labs, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Impact stockholders in connection with the proposed transaction. Information about Impact’s directors and executive officers is set forth in Impact’s filings with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Registration Statement and the Proxy statement/Prospectus included therein.

About Zoar Ltd:
Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:
Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Registration Statement, the proposed Business Combination, remaining conditions to closing, expected ownership and listing of PubCo shares, and the anticipated combined business. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected, including the risk that the Registration Statement is not declared effective on the anticipated timeline or at all, that Impact stockholders do not approve the transaction, that NYSE American does not approve the listing of PubCo shares, that other closing conditions are not satisfied or waived, or that the merger and share exchange agreement is terminated. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release.

No Offer or Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transaction and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com

Webinar Follows Recent Business Update Highlighting 3X Omni One Order Growth and Expanding Defense and Enterprise Opportunities

AUSTIN, Texas, Sept. 16, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced that it will hold a virtual investor webinar on Friday, September 18, 2026, at 10:00 a.m. Eastern Time.

Virtuix Chief Executive Officer Jan Goetgeluk will give an overview of the company’s growth strategy, near-term priorities, and recent commercial successes and developments, including its accelerating consumer momentum, expanding defense programs, and potential strategic acquisition.

In a recent business update, the Company highlighted that the number of Omni One orders are up approximately 3X quarter-to-date compared with the same period last year, following the June launch of Omni One for Quest in collaboration with Meta.

The Company also highlighted progress across multiple U.S. Department of Defense programs; repeat Omni One Enterprise orders from Tesla for its Optimus humanoid robot program; additional enterprise sales to organizations including NASA; and a potential strategic acquisition in the defense sector of a target whose annual revenues are near the upper end of the Company’s previously announced target range of $10 million to $50 million, at a valuation and financing structure that, if completed, the Company believes could create significant value for Virtuix shareholders.

Mr. Goetgeluk will be joined by Mr. David Allan, Virtuix’s President and Chief Operating Officer, and Ms. Lauren Premo, Virtuix’s Chief Marketing Officer. A question-and-answer session will follow.

The virtual investor webinar will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call on the Company’s investor relations website here.

To attend the webinar or watch the replay following the event, please use the following information:

Date:	Friday, September 18, 2026
Time:	10:00 a.m. Eastern Time (7:00 a.m. Pacific time)
Registration:	https://app.livestorm.co/virtuix/virtuix-investor-webinar-91826

The replay can be viewed through the webinar link that you’ll receive after registration.

Investors who would like to submit their questions in advance can do so by sending them to VTIX@mzgroup.us.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.

Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expectations for continued consumer growth following the Meta integration; the timing, completion, funding, or scope of defense programs, including the AFWERX SBIR Phase II proposal and the Infantry Fireteam Trainer installation; the Company’s ability to progress from initial development programs toward larger defense contracts; the Company’s sales and expansion plans; plans to pursue and complete strategic acquisitions, including the potential transaction currently under negotiation; potential impacts of any acquisition on future revenues, operations, or shareholder value; the Company’s competitive position in the defense training market; and the potential for enterprise applications to represent an additional growth market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to: the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business and realize anticipated synergies or benefits; risks related to government contracting, including contract cancellations, modifications, delays, or funding changes; uncertainties regarding continued consumer demand and market acceptance of the Company’s products; competition in the VR, gaming, defense, and enterprise markets; dependence on third-party relationships, including the Meta partnership; the uncertainties related to general market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Visit Us on Social Media:

LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e7cbc54e-c626-4082-bfb5-0e095b1e0096